Platelet-activating factor antagonists

Allergologia et Immunopathologia

Volumn 25, Issue 5, 1997, Pages 249-258

  Negro Alvarez J M ^a,d   Miralles Lopez J C ^b   Ortiz Martinez J L ^c   Abellan Aleman A A ^a   Rubio Del Barrio, R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b Allergology Section   (Spain)

^c Allergic and Asthma Center   (Spain)

^d Residencial La Paloma A 1 ^*  (Spain)

Author keywords

PAF; PAF antagonists; Platelet activating factor

Indexed keywords

1 [2 [[5 (N OCTADECYLCARBAMOYLOXYMETHYL)TETRAHYDROFURFURYLOXY]HYDROXYPHOSPHINYLOXY]ETHYL]QUINOLINIUM; 1 ACETYL 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE)PIPERIDINE; 1 ETHYL 2 [[N [[[TETRAHYDRO 5 (OCTADECYLOXY) 3 FURYL]METHOXY]CARBONYL]ACETAMIDO]METHYL]PYRIDINIUM CHLORIDE; 1 ETHYL 2 [N (2 METHOXYBENZOYL) N [2 METHOXY 3 [4 (OCTADECYLCARBAMOYLOXY)PIPERIDINOCARBONYLOXY]PROPOXYCARBONYL]AMINOMETHYL]PYRIDINIUM CHLORIDE; 1 METHYL 3 [1 [5 METHYLTHIOMETHYL 6 OXO 3 (2 OXO 3 CYCLOPENTEN 1 YLIDENE) 2 PIPERAZINYL]ETHYL] 2 INDOLINONE; 1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID METHYL 2 PHENYLTHIOETHYL ESTER; 2 [N (2 METHOXY 3 OCTADECYLCARBAMOYLOXYPROPOXYCARBONYL)ACETAMIDOMETHYL] 1 ETHYLPYRIDINIUM CHLORIDE; 3 [2 [[2 (N OCTADECYLCARBAMOYLOXYMETHYL)TETRAHYDROFURFURYLOXY]HYDROXYPHOSPHINYLOXY]ETHYL]THIAZOLIUM; [2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE; AGLAFOLINE; BILOBALIDE; BN 50580; BN 50585; CHANTANCIN; CL 184005; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE DERIVATIVE; GINKGOLIDE J; KADSURENONE; LC 5507; PHOMACTIN DERIVATIVE; PREHISPALONE; SWIETEMOHONIN A; TETRAHYDROCANNABINOL 7 OIC ACID; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UR 10324;

CHEMICAL STRUCTURE; DRUG STRUCTURE; INFLAMMATION; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; PLATELET ACTIVATING FACTOR;

EID: 9844237007     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Hanahan DJ, Demopoulos CA, Liehr J, Pinckard RN. Identification of platelet-activating factor isolated from rabbit J Biol Chem 1980;255:5514-6.
2. Koltay M, Horford D Platelet-Activating Factor and its antagonists in allergic and inflammatory disorders. In. Townley RG, Agrawal DK, eds Immunopharmacology of allergic disease New York Marcel Dekker; 1996. págs. 463-89
3. Koltay M, Braquet PG. Platelet-Activating Factor antagonists. Clin Rev Allergy 1994;12 361-80
4. Braquet P, Hosford D Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents. J Ethnopharmacol 1991;32:135-9
5. Braquet P, Esanu A, Buisine E, Hosford D, Broquet C, Koltai M. Recent progress, in ginkgolide research Med Res Rev 1991;11:295-355.
6. Hux JR. The pharmacology of extinction J Ethnopharmacol 1992;37 1-11
7. Smith PF, Maclennan K, Darlington CL. The neuroprotective properties of the Ginkgo biloba leaf a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacol 1996;50 131-9.
8. Corey EJ, Gavai AV Enantioselective route to a key intermediate in the total synthesis of ginkgolide B. Tetrahedron Lett 1988;29:3201-4.
9. Corey EJ, Rao KS Enantioselective total synthesis of ginkgolide derivatives lacking the tertbutyl group, an essential structural subunit for antagonism of platelet activating factor. Tetrahedron Lett 1991;32 4623-6
10. Shen TY, Hwang SB, Chang MN, Doebber TW, Lam MH, Wu MS, et al. Characterization of a platelet-activating factor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects Proc Nati Acad Sci USA 1985;82:672-6.
11. Sugano M, Shindo T, Sato A, lijima Y, Oshima T, Furuya K, et al. Phomactin A. a novel PAF antagonist from marine fungus Phonw sp J Am Chem Soc 1991;113:5463-4
12. Sugano M, Shindo T, Sato A, lijima Y, Oshima T, Kuwano H, et al Chantancin, a PAF antagonist from soft coral, Sacrophyton sp J Org Chem 1990;55:5802-5.
13. Ekimoto H, Irie Y, Araki Y, Han GQ, Kadota S, Kikuchi T Platelet aggregation inhibitors from the seeds of Swietenia mahagoni: inhibition of in vitro and in vivo platelet-activating factor induced effects of tetranortnterpenoids related to swietenine and swietenolide. Planta Med 1991;57:56-8.
14. Lee CM, Jiang LM, Shang HS, Hon PM, He Y, Wong HN. Prehispanolone, a novel platelet activating factor receptor antagonist from Leonorus heterophyllus. Br J Pharmacol 1991;103:1719-24.
15. Burstein SH, Audette CA, Doyle SA, Hull K, Hunter SA, Latham V. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid J Pharmacol Exp Ther 1989;251:531-5.
16. Ko FN, Wu TS, Liou MJ, Huang TF, Teng CM. PAF antagonism in vitro and in vivo by aglafoline from Aglaia elliptifolia Merr Eur J Pharmacol 1992;218:129-35
17. Hemmi K, Shimazaki N, Shima I, Okamoto M, Yoshida K, Hashimoto M. PAF antagonists from microbial origin: structure-activity relationships of diketopiperazine derivatives. In Braquet P, ed. Handbook of PAF and PAF Antagonists. Boca Raton: CRC Press; 1991. págs. 71-9
18. Shimazaki N, Shima I, Okamoto M, Yoshida K, Hemmi K, Hashimoto M PAF inhibitory activity of diketopiperazines structure-activity relationships Lipids 1991;26:1175-8
19. Femández-Gallardo S, Ortega MP, Priego JG, de Casa Juana MF, Sunkel C, Sánchez-Crespo M. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist in vivo studies J Pharmacol Exp Ther 1990;255:34-9
20. Biliah MM, Chapman RW, Egan RW, Gilchrest H, Piwinski JJ, Sherwood J, et al. SCH 37370, a potent, orally active, dual antagonist of platelet-activating factor and histamine. J Pharmacol Exp Ther 1990;252 1090-6
21. Carceller E, Merlos M, Giral M, Balsa D, Almansa C, Bartroli J, et al [(3Pyridylalkyl)piperidylidene] benzocycloheptapyridine derivatives as dual antagonist of PAF and histamine J Med Chem 1994;37:2697-703.
22. Takatani M, Tsushima S. Structure activity relationship in CV-3988 and CV-6209 PAF antagonist series In. Braquet P, ed. Handbook of PAF and PAF Antagonists Boca Raton CRC Press; 1991. págs. 97-118
23. Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents J Pharmacol Exp Ther 1992;260:748-55
24. Terashita Z, Imura Y, Takatani M, Tsushima S, Nishikawa K CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo J Pharmacol Exp Ther 1987,242:263-8.
25. Terashita Z, Takatani M, Nishikawa K. Pharmacological profile of TCV-309 a potent PAF antagonist. J Lipid Mediat 1992;5:183-5
26. Houlihan WJ Structure activity relationship in cyclic analogs of PAF with PAF antagonist properties. In Braquet P. ed. Handbook of PAF and PAF Antagonists Boca Raton. CRC Press, 1991. págs. 157-70.
27. Merlos M, Gomez LA, Giral M, Vericat ML, García-Rafanell J, Forn J. Effects of PAF-antagonists in mouse ear oedema induced by severa inflammatory agents. Br J Pharmacol 1991;104:990-4
28. Nagaoka J, Harada K, Kimura A, Kobayashi S, Murakami M, Yoshimura T. et al. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4-octadecylcarbamoyloxy) piperidino carbonyloxypropyloxy] carbonyamino methyl pyndinium chloride, in several experimentally induced shock models Arzneimittelforschung 1991,41:719-24.
29. Wissner A, Carroll ML, Green KE, Kerwar SS, Pickett WC, Schaub RE, et al Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet-activating factor J Med Chem 1992;35:1650-62
30. Wissner A, Carroll ML, Johnson BD, Kerwar SS, Pickett WC, Schaub E, et al. Analogues of platelet activating factor 7. Bisaryl amide and bis-aryl urea receptor antagonists of PAF J Med Chem 1992;35:4779-89
31. Tilley JW, O'Donnell M. N-[w-(Heteroalkyl) alkyl] carboxamide derivatives as platelet activating factor antagonists structure-activity relationships, and biological data. In. Braquet P, ed. Handbook of PAF and PAF Antagonists. Boca Raton: CRC Press; 1991. págs. 229-58.
32. Yin M, Buurman WA, Daemen JW, Kootstra G. The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. Transplantation 1996;61:1443-6.
33. Okano S, Tagawa M, Urakawa N Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock. J Veterinary Med Sci 1995;57:751-3.
34. Casals-Stenzel J Thieno-triazolo-1,4-diazepines as antagonists of platelet-activating factor present status. Lipids 1991,26 1157-61.
35. Heuer HO. WEB 2347: pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs. J Lipid Mediat 1991;4 39-44.
36. Heuer HO. Inhibition of active anaphylaxis in mice and guinea pigs by the new hetrazepinoic PAF antagonist bepafant (WEB 2170) Eur J Pharmacol 1991;199:157-63.
37. Spiegel HU, Oldhafer KJ, Lang H, Schuettler W, Bremer C, Pichlmayr R Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation Transplantation Proceedings 1995;27:2884-5.
38. Heuer HO, Keller B, Urich K. Action of the racemate and the isomers of the platelet-activating factor antagonist bepafant (WEB 2170) after oral administration to guinea-pigs and rats. Naunyn Schmiedebergs Arch Pharmacol 1991;343:546-50.
39. Foster AP, Lees P, Andrews MJ, Cunningham FM. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse. Equine Vet J 1992;24:203-7.
40. Da Silva MB, Herion F, Raskinet R, David JL, Gustin P, Dessy C, et al Inhibition of PAF-induced platelet aggregation by WEB 2086 «in vitro», an antagonist to the receptor for platelet-activating factor, in bovine Zentralblatt Veterinarmedizin 1996;43:399-413
41. Hayes JP, Ridge SM, Griffith S, Barnes PJ, Chung KF Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man. J Allergy Clin Immnunol 1991;88:83-8.
42. González-Fajardo JA, Fernández L, Álvarez T, Aguirre B, Ramos G, Vaquero C Protective effect of a platelet-activating factor antagonist (WEB-2086) in postischemic renal failure Ann Vascular Surg 1996;10:16-21
43. Cakici I, Mataraci N, Ersoy S, Tunctan B, Abacioglu N, Kanzik I. Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias. Pharm Toxicol 1995;76 343-7
44. Terasawa M, Aratani H, Setoguchi M, Tahara T. Pharmacological actions of Y-24180. I. A potent and specific antagonist of platelet activating factor. Prostaglandins 1990;40:571-9
45. Takehara S, Mikashima H, Muramoto Y, Terasawa M, Setoguchi M, Tahara T. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II Interactions with PAF and benzodiazepine receptors Prostaglandins 1990;40:571-83.
46. Hozawa S, Haruta Y, Ishioka S, Yamakido M. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am J Resp Crit Care Med 1995;152(4 pt 1):1198-202.
47. Sakuma Y, Muramoto K, Harada K, Katayama S, Tsunoda H, Katayama K. Inhibitory effect of a novel PAF antagonist E 6123 on anaphylactic responses in passively and actively sensitized guinea pigs and passively sensitized mice Prostaglandins 1991;42 541-55.
48. Karasawa A, Rochester JA, Lefer AM Beneficial actions of BN 50739, a new PAF antagonist, in murine traumatic shock Methods Find Exp Clin Pharmacol 1990;12:231-7.
49. Tsunoda H, Sakuma Y, Shirato M, Obaishi H, Harada K, Yamada K, et al. Activity of a novel thienodiazepine derivative as a platelet-activating factor antagonist in guinea pig lungs. Effects on platelet-activating factor and allergen induced eosmophil accumulation Arzneimittelforschung 1991;41:224-7.
50. Karasawa A, Rochester JA, Lefer AM. Beneficial actions of BN 50739, a new PAF antagonist, in murine traumatic shock. Methods Find Exp Clin Pharmacol 1990;12 231-7.
51. Braquet P, Esanu A New trends in PAF antagonist research: a new series of potent hetrazepine derived PAF antagonists Agents Actions 1991;32:34-6.
52. Braquet P, Laurent B, Rolland A, Martin C, Pommier J, Hosford D, et al. From ginkgolides to N-substituted piperidinothienodiazepines, a new series of highly potent dual antagonists. Adv Prostaglandins Tromboxane Leukot Res 1990;21:929-37.
53. Castaner J, Koltai M, Spinnewyn B, Duverger D, Pirotzky E, Esanu A, et al. BN 50739 Drugs Future 1990;16:413-9.
54. Yue TL, Rabinovici R, Farhat M, Feuerstein G. Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo. Prostaglandins 1990;39:469-80.
55. Yue TL, Rabinovici R, Farhat M, Feuerstein G. Inhibitory effect of a new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo. J Lipid Mediat 1991;3:13-26
56. Rabinovici R, Yue TL, Farhat M, Smith EF, Esser KM, Slivjak M, et al Platelet activating factor (PAF) and tumor necrosis factor-a (TNFa) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist. J Pharmacol Exp Ther 1990; 55:256-63.
57. Lindsberg PJ, Hallenbeck JM, Feuerstein G. Platelet-activating factor in stroke and brain injury. Ann Neurol 1991;30:117-29
58. Pires ALA, Silva PMR, Pasquale C, Castro-Faria-Neto HC, Bozza PT, Cordeiro RSB, et al. Long-lasting inhibitory activity of the hetrazepinic BN 50730 on exudation and cellular alterations evoked by PAF and LPS. Br J Pharmacol 1994;113 994-1000.
59. Dyson MC, Bellan JA, Minkes RK, Beckerman RC, Wegman MJ, Braquet P, et al. Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat. J Pharmacol Exp Ther 1990;255:1320-7.
60. Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, et al Pharmacology of a potent platelet-activating factor antagonist. Ro 24-4736 J Pharmacol Exp Ther 1991; 259:78-85.
61. Lave D Structure-activity relationships in pyrrolo [1,2-c] thiazoles PAF receptor antagonists In. Braquet P, ed. Handbook of PAF and PAF Antagonists Boca Raton: CRC Press, 1991. p. 203-28
62. Floch A, Bousseau A, Hetier E, Floch F, Bost PE, Cavero I. RP 55778, a PAF receptor antagonist, prevents and reserves LPS-induced hemoconcentration and TNF release. J Lipid Mediat 1989;1:349-60
63. Floch A, Tahraoui L, Sedivy P, Cavero I. The platelet activating factor receptor antagonist, RP 59227, blocks platelets activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polynuclear leukocytes J Pharmacol Exp Ther 1991;258:567-75
64. Underwood SL, Lewis SA, Raeburn D. RP 59227, a novel PAF receptor antagonist effects in guinea pig models of airway hyperreactivity. Eur J Pharmacol 1992;210:97-102.
65. Yamada T, Tomioka K, Hone M, Sakurai Y, Nagaoka H, Mase T. Effects of YM 264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun 1991;176:781-5
66. Yamada T, Tomioka K, Saito M, Hone M, Mase T, Nagaoka H Pharmacological properties of YM 264, a potent and orally active antagonist of platelet-activating factor Arch Int Pharmacodyn Ther 1990;308:123-36.
67. Yamada T, Saito M, Mase T, Hara H, Nagaoka H, Murase K et al. Pharmacological properties of YM 461, a new orall active platelet-activating factor antagonist. Lipids 1991;26 1179-83.
68. Imanishi N, Komuro Y, Morooka S Effect of a selective PAF antagonist SM-10661 I(±)-cis-3,5, dimethyl-2-(3-pyridyl) thiazolidin-4-one Hcl] on experimental disseminated intravascular coagulation (DIC). Lipids 1991;26:1391-5.
69. Komuro Y, Imanishi N, Uchida M, Morooka S. Biological effects of orally active platelet activating factor receptor antagonist SM-10661. Mol Pharmacol 1990;38 378-84.
70. Sugasawa T, Imanishi N, Morooka S Effect of the selective PAF antagonist SM-10661 in an asthmatic model. 2. The effect of antigen-induced dual asthmatic response and infiltration of leukocytes into airways in actively sensitized conscious guinea pigs. Lipids 1991;26:1305-9
71. Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC et al. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet activating factor receptor antagonist J Pharmacol Exp Ther 1991;259:44-51.
72. Herbert JM, Laplace MC, Bernat A.,Salel V, Maffrand JP Effect of SR 27417 on oedema formation induced in rabbit skin by platelet-activating factor or antigen. Eur J Pharmacol 1992;216:175-81.
73. Sanz MJ, Weg VB, Walsh DT, Williams TJ, Nourshargh S. Differential effects of the PAF receptor antagonist UK-74505 on neutrophil and eosinophil accumulation in guinea-pig skin. Br J Pharmacol 1994;113:513-21.
74. Parry MJ, Alabaster VA, Cheeseman HE, Cooper K, De Souza RN, Keir RF Pharmacological profile of UK-74505, a novel and selective PAF antagonist with potent and prolonged oral activity. J Lipid Mediators Cell Signalling 1994;10:251-68
75. Alabaster VA, Keir RF, Parry MJ, de Souza RN UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. Agents Actions 1991;34:221-7.
76. Weber KH, Heuer HO Hetrazepines as antagonists of platelet activating factor. Med Res Rev 1989;9 181-218.
77. Shen TY Chemical and biochemical characterization of lignan analogs as novel PAF receptor antagonists Lipids 1991;26 1154-6
78. Dive G, Godfroid JJ, Lamotte-Brasseur J, Batt JP, Heymans F, Dupont L, et al PAF receptor I «Cache-oreilles» effect of selected high potency platelet-activating factor (PAF) antagonists J Lipid Mediat 1989;1 201-15
79. Batt JP, Lamouri A, Tavet F, Heymans F, Dive G, Godfroid JJ New hypothesis on the conformation of the PAF receptor from studies on the geometry of selected platelet-activating factor antagonists J Lipid Mediat 1991;4 343-6.
80. Ponpipom MM, Hwang SB, Doebber TW, Acton JJ, Alberts AW, Bitfu T et al (+/-) trans-2-(3-Methoxy-5methyl sulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl) tetra hydrofuran (L-659,989), a novel, potent PAF-receptor antagonist, [published erratum appears in Bioch Biophys Res Commun 1988;192:949] Biochem Biophys Res Commun 1988;150 1213-20
81. Girotra NN, Biftu T, Ponpipom MM, Acton JJ, Alberts AW, Bach TN et al Development, synthesis, and biological evaluation of (-)-trans(2S,5S|-2-[3-[2-oxopropyl)sulfonyl]-4-n-propoxy5(3hydroxypropoxy- phenyl)-5-(3,4,5trimethoxy phenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water soluble prodrug phosphate ester. J Med Chem 1992;35:3474-82.
82. Alvaro RF, Rosegay A, Chiu SH. Determination of enantiomeric concentrations of a 2,5-diaryltetrahydrofuran (L-668.750), a platelet-activating factor antagonist, in the rat plasma using a chiral alpha 1-acid glycoprotein bigh-performance liquid chromato-graphy column. J Chromatogr 1992;578:327-32
83. Ko FN, Yu SM, Chen IS, Ishii H, Chang YL, Huang TF, Teng CM. CIS-19, a novel platelet activating factor receptor antagonist, in vitro and in vivo studies. Biochim Biophys Acta 1993;1175:225-31.
84. Albert DH, Conway RG, Magoc TJ, Tapang P, Rhein DA, Luo G et al Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist J Pharmacol Exp Ther 1996;277 1595-606
85. Albert DH, Luo G, Magoc TJ, Tapang P, Holms JH, Davidsen SK, et al ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats Shock 1996;6:112-7
86. Yang HO, Kang YH, Suh DY, Kim YC, Han BH. Biological and pharmacological effects of pinusolide, a novel platelet activating factor antagonist. Planta Médica 1995;1:519-22